ACRS

Aclaris Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Aclaris Therapeutics sales and earnings growth
ACRS Growth
Low
  • Revenue Y/Y↓ -41.87%
  • EPS Y/Y↓ -203.85%
  • FCF Y/Y↓ -132.97%
Aclaris Therapeutics gross and profit margin trends
ACRS Profitability
Low
  • Gross margin ↓ 4.00%
  • EPS margin↓ -900.00%
  • ROIC↓ -99.10%
Aclaris Therapeutics net debt vs free cash flow
ACRS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Aclaris Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Diagnostics & Research stocks ↗